Fig. 5

β-Galactosidase staining analysis of leukemia cells treated with LEE011. Leukemia cells were treated with 2.0 µM LEE011 for 24–72 h before analysis; more cells stained β-galactosidase positive in the LEE011-treatment group compared with the DMSO control group. For MV4-11 cells, 3-days-treated LEE011 group positive cells were 54.77 ± 6.68% vs. DMSO group 7.17 ± 0.95%, P = 0.006; in HL60 cells, 3-days-treated LEE011 group positive cells were 75.43 ± 12.67% vs. DMSO group 6.20 ± 1.00%, P = 0.0011; in NB4 cells, 3-days-treated LEE011 group positive cells were 82.10 ± 7.55% vs. DMSO group 7.17 ± 1.12%, P = 0.003. **P < 0.01